Holen Sie sich die Stockscreener-App
12.62
0.98%
-0.157
Schlusskurs vom Vortag:
$12.78
Offen:
$12.61
24-Stunden-Volumen:
72,010
Relative Volume:
0.06
Marktkapitalisierung:
$969.38M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-4.3678
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
+14.11%
1M Leistung:
+36.96%
6M Leistung:
+9.76%
1J Leistung:
-48.52%
1-Tages-Spanne:
$12.46
$12.78
1-Wochen-Bereich:
$11.19
$13.23
52-Wochen-Spanne:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
12.68 | 1.30B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.32 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
650.66 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.86 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
815.13 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.63 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
How institutional ownership impacts Nurix Therapeutics Inc. stock2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Full technical analysis of Nurix Therapeutics Inc. stockJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
How moving averages guide Nurix Therapeutics Inc. tradingMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
Will Nurix Therapeutics Inc. stock go up soonPortfolio Value Summary & Consistent Profit Trading Strategies - newser.com
Nurix Therapeutics CFO van Houte sells $40k in shares By Investing.com - Investing.com UK
Will Nurix Therapeutics Inc. stock deliver consistent dividendsQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Can Nurix Therapeutics Inc. recover in the next quarterEarnings Summary Report & Daily Momentum Trading Reports - newser.com
Nurix Therapeutics CLO ring sells shares for $46,631 By Investing.com - Investing.com Canada
Nurix therapeutics CSO Hansen sells $52k in shares By Investing.com - Investing.com Philippines
Nurix Therapeutics CFO van Houte sells $40k in shares - Investing.com
Nurix therapeutics CSO Hansen sells $52k in shares - Investing.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Nurix Therapeutics (Nasdaq: NRIX) to join Stifel Nov 13 and Jefferies Nov 19 webcasts - Stock Titan
Is Nurix Therapeutics Inc. building a consolidation baseInflation Watch & High Return Trade Guides - newser.com
HC Wainwright Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat
Visual trend scoring systems applied to Nurix Therapeutics Inc.July 2025 Retail & Technical Confirmation Trade Alerts - newser.com
AlphaQuest LLC Boosts Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics Inc. stock daily chart insightsJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com
What technical charts say about Nurix Therapeutics Inc. stockTrade Risk Report & Low Risk High Reward Ideas - newser.com
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.7% HigherHere's Why - MarketBeat
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Nurix stock price target lowered to $28 at H.C. Wainwright on trial updates - Investing.com UK
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 34% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Will Nurix Therapeutics Inc. bounce back from current supportWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Applying chart zones and confluence areas to Nurix Therapeutics Inc.Weekly Trade Report & Long-Term Growth Stock Strategies - newser.com
Nurix Therapeutics closes $250 million stock offering By Investing.com - Investing.com Philippines
Why Nurix Therapeutics Inc. stock is seen as undervaluedQuarterly Trade Review & Safe Swing Trade Setup Alerts - Fundação Cultural do Pará
Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Nurix Therapeutics Advances NX-5948 Study in B-cell Malignancies - TipRanks
Nurix Therapeutics’ NX-2127 Study: A Potential Game-Changer in B-cell Malignancy Treatment - TipRanks
Nurix Therapeutics’ NX-5948 Study: A Potential Game-Changer in Drug Delivery - TipRanks
Fenwick Represents Nurix Therapeutics in its $250M Registered Common Stock Offering - fenwick.com
Nurix Therapeutics closes $250 million stock offering - Investing.com
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock - Investing News Network
Nurix (NASDAQ: NRIX) closes 24.5M-share offering at $10.21 for CLL, autoimmune - Stock Titan
Leerink Partnrs Has Bullish Outlook for NRIX FY2025 Earnings - MarketBeat
Can Nurix Therapeutics Inc. stock hit record highs againJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nurix Therapeutics Inc-Aktie (NRIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
Oct 30 '25 |
Sale |
12.80 |
3,130 |
40,054 |
43,876 |
| Ring Christine | Chief Legal Officer |
Oct 30 '25 |
Option Exercise |
0.00 |
10,532 |
0 |
54,541 |
| Ring Christine | Chief Legal Officer |
Oct 30 '25 |
Sale |
12.80 |
3,644 |
46,631 |
50,897 |
| Hansen Gwenn | Chief Scientific Officer |
Oct 30 '25 |
Option Exercise |
0.00 |
11,815 |
0 |
80,838 |
| Hansen Gwenn | Chief Scientific Officer |
Oct 30 '25 |
Sale |
12.80 |
4,087 |
52,300 |
76,751 |
| GREGORY JULIA P | Director |
Sep 17 '25 |
Option Exercise |
1.86 |
10,750 |
19,995 |
10,750 |
| van Houte Hans | Chief Financial Officer |
Aug 01 '25 |
Sale |
11.03 |
5,402 |
59,598 |
35,512 |
0.11%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):